Seroquel XR Remission Claims Challenged By FDA As AstraZeneca Puts Lawsuits To Rest
This article was originally published in The Pink Sheet Daily
Executive Summary
"Remission" has no regulatory definition in major depressive disorder, FDA says in letter citing a sales rep aid left with doctors.
You may also be interested in...
AstraZeneca Settles Seroquel Suits For A Third Of What Lilly Paid For Zyprexa
In deciding to settle rather than continue to litigate Seroquel (quetiapine) product liability claims, AstraZeneca is following the path Lilly took in resolving suits over its antipsychotic Zyprexa (olanzapine). But the financial burden won't be as heavy for AstraZeneca
AstraZeneca Settles Seroquel Suits For A Third Of What Lilly Paid For Zyprexa
In deciding to settle rather than continue to litigate Seroquel (quetiapine) product liability claims, AstraZeneca is following the path Lilly took in resolving suits over its antipsychotic Zyprexa (olanzapine). But the financial burden won't be as heavy for AstraZeneca
AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges
AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement